Salovum Egg Yolk Containing Antisecretory Factor As an Adjunct Therapy in Severe Cholera in Adult Males: A Pilot Study by Alam, Nur H. et al.
©INTERNATIONAL CENTRE FOR DIARRHOEAL
DISEASE RESEARCH, BANGLADESH
J HEALTH POPUL NUTR  2011 Aug;29(4):297-302
ISSN 1606-0997 | $ 5.00+0.20
Dr. N.H. Alam
Clinical Sciences Division 
icddr,b
GPO Box 128, Dhaka 1000
Bangladesh
Email: nhalam@icddrb.org
Salovum Egg Yolk Containing Antisecretory  
Factor As an Adjunct Therapy in Severe  
Cholera in Adult Males: A Pilot Study
Nur H. Alam1, Hasan Ashraf1, Maryam Olesen2, Mohammed A. Salam1, 
Niklaus Gyr3, and Remy Meier4
1icddr,b, GPO Box 128, Dhaka 1000, Bangladesh, 2Novartis Consumer Health, Bern, Switzerland, 3University Hospital Basel, 
Basel, Switzerland, and 4Gatroenterology Department, University Hospital, Liestal, Switzerland
ABSTRACT
Cholera involves stimulation of intestinal secretory process in response to cholera toxin leading to profuse 
watery diarrhoea that might cause death due to dehydration unless timely rehydration therapy is initia- 
ted. Efforts to identify and test potential antisecretory agents are ongoing. Antisecretory factor (AF) is a 
naturally-occurring protein produced in the human secretory organs, including the intestine, with antisec-
tory properties demonstrated in animal and human models of secretory diarrhoea. Salovum egg yolk pow-
der contains proteins with antisecretory properties in a much higher (500 times) concentration than that 
of normal hen eggs. This is achieved by feeding hens with specially-processed cereals, capable of inducing 
proteins with antisecretory properties in the yolk. The aim of the study was to examine the effect of Salo-
vum egg yolk powder containing AF in the treatment of adult cholera patients. In an open, randomized 
controlled trial (pilot study), 40 adult male patients with severe cholera were studied: 20 received standard 
treatment (oral rehydration solution, antibiotic, and usual hospital diet) plus Salovum egg yolk powder 
(study group) and 20 received standard treatment alone (control group). All the patients received tablet 
doxycycline (300 mg) once immediately after randomization. Written informed consent was obtained 
from each subject before enrollment. The main outcome measures were stool weight and duration of diar-
rhoea. The demographic and baseline clinical characteristics of the study patients were comparable between 
the groups. No significant differences were found in the mean stool weight, g/kg of body-weight during 
the first 24 hours [study vs control group, mean±standard deviation (SD), 218±119 vs 195±136], second 24 
hours (mean±SD, 23±39 vs 22±34), and cumulative up to 72 hours (mean±SD, 245±152 vs 218±169). The 
duration (hours) of diarrhoea after admission in the hospital was also similar in both the groups (mean±SD, 
33±14 vs 32±10). No adverse effect was observed. Salovum egg powder containing AF as an adjunct therapy 
in the treatment of severe cholera could not demonstrate any beneficial effect. Further studies with higher 
doses of Salovum egg yolk powder might be considered in future to establish its antisecretory effect.
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INTRODUCTION
Vibrio cholerae is the enteric bacterial pathogen 
that causes cholera. The disease can often be very 
severe characterized by frequent passage of vo-
luminous watery stools and vomiting leading to 
severe dehydration and, if not efficiently treated, 
might result in death; the rates can be as high as 
50-80% (1). Prevention of dehydration, rehydra-
tion using appropriate oral or intravenous fluids, 
and the use of an effective antimicrobial agent, 
along with continued feeding, are important in the 
case-management strategy of cholera (2,3). Since 
cholera involves stimulation of secretory process 
in response to cholera toxin produced by V. chol-
erae, efforts to identify and test potential antisecre-
tory agents to reduce the severity of diarrhoea are 
ongoing. Most of these agents assessed so far have 
no or minimal effect (4-15). Until now, none of the 
antisecretory agents has been recommended for 
the clinical management of cholera patients. 
As possible antisecretory agents, some endogenous 
factors have recently drawn the attention of re-Alam NH et al. Salovum egg powder in treatment of severe cholera
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searchers. Antisecretory factor (AF), a naturally-oc-
curring protein, is produced in the brain and in the 
secretory organs, such as gallbladder, lungs, kidneys, 
and the intestine, in response to infection (16-20). 
AF is also secreted in blood, bile, and breastmilk in 
response to intestinal enterotoxin challenge (21), 
and the content in sows’ milk is probably crucial 
for protection against neonatal diarrhoea in suck-
ling piglets (22). It has also been found that car-
bohydrates and amino acids of specially-processed 
cereals are also able to induce secretion of AF or 
AF-like proteins (23,24), which might be useful for 
therapeutic applications. Preclinical animal studies 
have shown that AF can have both prophylactic 
and therapeutic applications in the treatment of 
various types of diarrhoea (25-29). Results of hu-
man studies also demonstrated that AF possesses 
strong anti-inflammatory properties (30-32). 
The Salovum egg yolk powder contains protein 
with antisecretory properties in a much higher 
(500 times) concentration than found in normal 
hen eggs. This is achieved by feeding hens with 
specially-processed cereals, capable of inducing 
production of protein with antisecretory properties 
in the yolk, from which an egg powder is produced 
(33,34). In view of its apparent antisecretory and 
anti-inflammatory effects, AF could be therapeuti-
cally useful in diarrhoeal diseases of various aetiolo-
gies. Therefore, we evaluated the effect of salovum 
egg yolk powder containing AF in the management 
of adult male cholera patients.
MATERIALS AND METHODS
This open, controlled (pilot study) clinical trial was 
conducted among 40 adult patients to evaluate the 
effect of AF-rich Salovum egg yolk powder as an 
adjunct therapy in the management of severe cho-
lera. The study patients were selected from among 
those attending the Dhaka Hospital of icddr,b from 
June to December 2005. The Ethics Review Com-
mittee of icddr,b approved the protocol. Adult 
male patients who attended the Dhaka Hospital for 
treatment were screened for eligibility. All patients 
aged 18-55 years with a history of watery diarrhoea 
of <24 hours and signs of severe dehydration and 
initial stool dark-field microscopy positive for V. 
cholerae were eligible for participation in the study. 
Patients with a history of chronic diarrhoea, dys-
entery, receiving antimicrobial or antidiarrhoeal 
drugs within one week before admission, renal or 
hepatic dysfunction, known allergies to eggs, and 
refusal of written informed consent were excluded 
from the study. Upon initial screening, patients 
were brought to the research ward of the hospital, 
weighed, and placed on a cholera cot. A standard 
medical history, thorough physical examinations, 
including assessment of dehydration using the 
modified guidelines of the World Health Organ-
ization (WHO) (35), and vital signs were recorded 
in pre-designed forms. Before randomization in 
the study, all the patients were rehydrated with 
intravenous (IV) fluids containing polyelectrolytes 
(Na 133, Cl 98, K 13, and acetate equivalent to 48 
mmol/L of bicarbonate) at a rate of 100 mL/kg of 
body-weight over 4-6 hours, in addition to replace-
ment of ongoing losses in stool and vomit. 
The enrollment of patients in the study was done 
every day from 6 am to 2 pm when most severely-
dehydrated patients attend the hospital. In total, 
68 adult male patients with suspected cholera were 
screened at the hospital, of whom 40 were rando- 
mized to treatment (trial profile in Fig. 1). The 
main reasons for the exclusion of 28 patients were: 
22 being V. cholerae negative by dark-field micros-
copy and six refused to provide consent to partici-
pate in the study.
Randomization
Eligible patients who fully rehydrated within 4-6 
hours were randomized in equal numbers to receive: 
(a) AF (2 sachets of Salovum egg yolk powder—2 
g each, i.e. total 4 g, were dissolved in 100 mL of 
oral rehydration salt solution (ORS) and fed orally 
every two hours during the first 24 hours and then 
four hourly until the resolution of diarrhoea but up 
to a maximum of 72 hours), in addition to stand-
ard treatment (ORS, antibiotic, and usual hospital 
diet) or (b) the standard treatment (ORS, antibiotic, 
and usual hospital diet) alone. The dose decided 
was partly arbitrary and was based on a previous 
68 patients screened
for eligibility
40 randomized
to either study or
control group
Fig. 1.Trial proﬁle
20 received 
Salovum egg yolk 
powder in addi-
tion to standard 
treatment (study 
group)
20 received 
standard treatment 
(control group)
28 excluded from 
the study: 22 did 
not meet inclusion
criteria, and 6 did 
not consent
to participate  Alam NH et al.
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study among patients with inflammatory bowl 
disease; the dose used 4 g four hourly for 14 days. 
Since cholera is an acute severe disease, we decided 
frequent dosing (2 hourly) at least for 24 hours. A 
trained staff of icddr,b, not involved in the study, 
prepared the randomization list, and the name of 
intervention was indicated on a paper, kept inside 
the sealed envelopes. The sealed envelopes were 
kept with the pharmacists of the Dhaka Hospital as 
they were not involved in the study. After receiv-
ing the name, the study serial number, and the 
hospital number of the patient to be randomized, 
the pharmacist opened the sequentially-numbered 
sealed envelopes, starting with the lowest number 
and moving towards higher numbers and supplied 
the sachet of Salovum egg yolk powder or informed 
about control (standard treatment alone).
Case management
Immediately after randomization (following IV re-
hydration), maintenance oral rehydration therapy 
was started using the WHO-recommended ORS (Na 
75, glucose 75, Cl 65, K 20, and citrate 10 mmol/L 
and osmolarity 245 mosmol/L). During mainte-
nance, patients consumed ORS according to need, 
with minimum volume equal to continued loss 
of watery/loose stool and vomit. All the patients 
received capsule doxycycline (300 mg) as a single 
dose within 20 minutes of randomization into the 
study. A standard diet was provided according to 
the hospital practice (breakfast at 6:30 am, lunch 
at 12 noon, and supper at 6 pm). Plain water was 
allowed as desired by the patients preferably after 
food. IV fluid therapy was restarted in some pa-
tients where signs of severe dehydration reappeared 
despite appropriate ORS therapy or where excessive 
vomiting prevented successful oral therapy. Stool 
was collected in a bucket placed underneath the 
cholera cot. All intakes (IV fluid, ORS, and water) 
and outputs (stool, urine, and vomit) were meas-
ured and recorded every six hours during the study 
until discharge. Weight of stool was measured with 
an electronic scale with a precision of 1 g (Sartorius, 
Germany). Urine was separated in a urine collector 
and measured with a calibrated cylinder. Weight of 
vomit was measured by collection in a pre-weighed 
bowl by subtracting the weight of the bowl. The 
volume of ORS and plain water consumed by the 
patients was measured with a calibrated cylinder. 
Body-weight was measured on admission (before 
initiation of IV therapy), at randomization (after IV 
rehydration), and every six hours until discharged, 
using the same electronic scale.
Laboratory investigations
Fresh stool samples were examined for V. cholerae by 
dark-field microscopy during the initial 4-6-hour IV 
rehydration period. Stool samples were cultured for 
the isolation and identification of V. cholerae, Sal-
monella, and Shigella using the standard techniques 
at randomization. Peripheral venous blood samples 
were tested for haematocrit, total and differential 
white blood cells, blood urea nitrogen, creatinine, 
serum sodium, potassium, chloride, and bicarbo-
nate at randomization and after 24 hours. 
All the patients were observed closely until dis-
charge. Resolution of diarrhoea was defined if pa-
tients did not pass any stool for at least 12 hours 
or if they passed two consecutive normal (formed) 
stools. Clinical success was defined as cessation of 
diarrhoea within 72 hours from the start of study 
medication, and those with continued watery stool 
for more than 72 hours were considered clinical 
failure. Oral therapy failure was defined as reap-
pearance of signs and/or symptoms of dehydra-
tion, requiring unscheduled IV fluid therapy. The 
duration (hours) of diarrhoea was calculated from 
the time of randomization to the last watery stool.
Analysis of data
All statistical analyses were performed using the 
SPSS PC+ software (version 10). All the statistical 
tests were two-tailed, performed at 5% level of sig-
nificance. The continuous variables were compared 
using the Student’s t-test, and the categorical varia-
bles were compared with the χ2 test or Fisher’s exact 
test as appropriate. Kaplan-Meier survival curves 
were constructed for the duration of diarrhoea and 
was compared by log rank test.
RESULTS
The demographic and baseline clinical characteris-
tics with regard to the patients’ age, body-weight, 
duration of diarrhoea before admission, duration 
of vomiting, stool (g)/kg of body-weight per hour 
during the IV rehydration period were comparable 
between the groups (Table 1). There were no sig-
nificant differences between the two treatments for 
the major outcome variables: stool output, ORS in-
take, and need for unscheduled IV fluids (Table 2). 
The mean duration of diarrhoea was also similar in 
both the groups. Kaplan-Meier survival curves (Fig. 
2) also showed a similar pattern in both the groups 
(p=0.83, log rank test). Serum electrolytes, blood 
urea nitrogen, and creatinine were within normal 
limits and were similar in both the groups (data not 
shown). No adverse experience, such as abdominal 
pain, any allergic skin manifestation, etc., was not-
ed during the study.Alam NH et al. Salovum egg powder in treatment of severe cholera
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Table 1. Demographic and clinical characteristics of study patients on admission
Variable
Salovum egg
(mean±SD)
(n=20)
Control
(mean±SD)
(n=20)
p value
Age (years) 23.65±4.80 24.90±6.28 0.25
Body-weight (kg) on admission 45.25±5.10 43.86±4.62 0.96
Duration (hours) of diarrhoea before admission  10±5 10±5 0.88
Number of stools before admission 14±9 15±8 0.57
Duration (hours) of vomiting before admission  7±4 8±5 0.26
Number of vomits before admission 8±7 10±8 0.42
Number of stools during the observation period 15±9 10±7 0.42
Received IV fluids (mL/kg of body-weight) during   
the IV rehydration period 192±28 181±37 0.27
Stool rate during the IV rehydration period 
(g/kg of body-weight/hour) 13.44±7.68 10.41 ± 7.55 0.60
IV=Intravenous; SD=Standard deviation
Table 2. Comparison of outcome variables of study patients
Variable
Salovum egg
(mean±SD)
(n=20)
Control
(mean±SD)
(n=20)
p value
Stool weight (g) on day 1/kg of body-weight 218±119 195±195 0.57
Stool weight (g) on day 2/kg of body-weight 23±39 22±34 0.87
Stool weight (g) cumulative/kg of body-weight 
up to 72 hours 245±152 218±169 0.60
ORS (mL) intake on day 1/kg of body-weight 279±107 245±108 0.32
ORS (mL) intake on day 2/kg of body-weight 42±54 46±59 0.82
ORS (mL) intake cumulative up to 72 hours/kg 325±143 295±169 0.55
Duration (hours) of diarrhoea  33±14 32±10 0.64
Number of patients received unscheduled IV fluid* 5 (25) 4 (20) 0.70
*Values are number (%); IV=Intravenous; ORS=Oral rehydration salt solution; SD=Standard deviation
DISCUSSION
The results of the study demonstrated that Salovum 
egg yolk powder rich in AF used as an adjunct thera- 
py as standard treatment of severe cholera failed 
Fig. 2.Kaplan-Meier survival curve for duration
            of diarrhoea
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to show any additional beneficial effect. It neither 
reduced the severity of illness by reducing stool 
output nor reduced the duration of diarrhoea. Al-
though results of studies in animal models showed 
its antisecretory effect, its efficacy in patients with 
secretory diarrhoea due to microbial pathogens was 
not previously proven (25-29). The reasons why 
the Salovum egg yolk powder containing AF did 
not work cannot be explained from this study. We 
can assume the possible causes as: (a) degradation 
of the protein with antisecretory properties while 
passing through the stomach to the small intestine, 
the main site of its action; (b) failure to work for 
the nature of the disease process in severe chol-
era where the intestinal transit time is very short 
and the material might have washed out before 
it could act; and (c) the dose of Salovum egg yolk 
powder used might not be adequate. Therefore, 
further clinical studies with larger doses might be 
planned in future. Recently, one study has shown Alam NH et al.
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the beneficial effect of Salovum egg yolk powder 
in terms of reducing the stool frequency and early 
recovery of children suffering from acute (duration 
of diarrhoea <7 days) and prolonged (duration of 
diarrhoea >7 days) non-cholera watery diarrhoea 
(36). However, this study is not comparable with 
our study, especially in relation to the study sub-
jects, aetiology, and pathophysilogy. It may be 
mentioned that the patients in the Salovum group 
had a greater frequency of stools and a higher stool 
volume (Table 1) during the observation period 
compared to the control group, although these 
trends were not significant. After intervention, the 
patients in the Salovum group had a higher stool 
volume on day 1, 2, and cumulative up to 72 hours 
and greater ORS intake on day 1 and cumulative 
up to 72 hours. They also had slightly longer dura-
tion of diarrhoea and an increased number of pa-
tients receiving unscheduled IV fluid compared to 
the control group but these trends were also not 
significant (Table 2). If the Salovum group did have 
patients who had a more severe state of cholera at 
baseline than the control group, this might conceal 
any beneficial effects of Salovum egg yolk powder. 
Conclusions
We conclude that the use of Salovum egg yolk pow-
der containing AF apparently did not provide any 
additional benefit in the treatment of severe chole- 
ra in adults. Although this was found to be safe for 
short-term evaluation, we do not have any infor-
mation on long-term adverse effects. Further stud-
ies with a larger sample-size and in different doses 
involving both cholera and non-cholera diarrhoea 
in children and adults are warranted to establish the 
efficacy of Salovum egg powder containing AFs.
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